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Generating a strong, long-lasting protective immune response is the goal of 
vaccination.  Skin is one of the most obvious and attractive vaccination site and activation of 
innate immune cells is a proven strategy in vaccination.  Despite the considerable 
improvement of injection devices, an unmet need for developing efficient vaccine adjuvants 
that induces little to no skin inflammation remains.  While using adjuvants can enhance the 
immunogenicity of the vaccination formula and reduce the amount of antigen required, 
adverse reactions have to be considered as they could outweigh its benefits.  Many current 
adjuvants induce severe skin inflammation that dramatically impacts the integrity of skin 
epithelia.  Although there has been great progress in the identification of new adjuvants 
adjuvant, alum remains the dominant adjuvant for human vaccines.  Even though many new 
adjuvant candidates have been evaluated over the years, most have failed to be successful 
in humans mainly because of toxicity, stability and cost.  Furthermore, each adjuvant 
induces a characteristic immunological differentiation program such as Th1, Th2 or Th17, 
independently of the antigen targeted.  An improved understanding of innate immune 
signaling should greatly contribute to the design more precise immunostimulants.  The 
discovery of the STING pathway, a central pathway in antiviral innate immunity opened up 
several new possibilities in this area.  STING agonists would be candidates for clinical 
testing as adjuvants and as stimulants for immune activity.  The most potent natural STING 
agonist in humans is 2′ 3′-cGAMP. 
Wang and colleagues demonstrate the great potential of 2’ 3’-cyclic GMP-AMP 
(cGAMP) adjuvant, the natural agonist of STING (Wang et al., 2016).  The immune 
responses generated by cGAMP a string and long-lasting, greatly enhancing immnological 
protection against pandemic influenza, more efficient in intradermal delivery than 
intramuscular and not toxic for the skin. 
The understanding of innate sensing of nucleic acids pathogen- or danger 
associated molecular patterns (PAMPs or DAMPs) is a critical step towards the 
improvement of the efficacy of vaccine formulations.  Cytosolic pattern recognition receptors 
that sense nucleic acids in the cytoplasm have recently been explored.  Immune sensing of 
nucleic acids is involved in both early innate defenses and subsequent bridging with 
adaptive immune responses (Stetson and Medzhitov, 2006).  Viral infection can be sensed 
by the recognition of nucleic acids of viral origin through structural features that aren’t founds 
in self nucleic acids.  By contrast toll-like receptors (TLRs) can sense RNA and DNA 
molecules of both exogenous and endogenous origin.  Recently, a new cytosolic DNA 
sensor pathway has been described in dendritic cells to trigger a cell-autonomous antiviral 
response associated with IFN- -GMP-AMP (cGAS), stimulator of 
interferon genes complex (STING) and interferon regulatory 3 (IRF3) (Lahaye et al., 2013; 
Sun et al., 2013).  In regards to the potential cell damage generated by viral infection or cell 
stress, it has been hypothetized that cGAS sensor is activatged by endogenous DNA 
(Marichal et al., 2011).  However, STING is also implicated in sensing RNA as the 
replication of RNA viruses is enhanced in its absence(Marichal et al., 2011), and in viral 
restriction as several RNA viruses can antagonize STING(Aguirre et al., 2012).  
Furthermore, it has been recently suggested that the RNA virus, influenza A H1N1, 
stimulates the production of interferon through a cGAS-independent STING pathway 
through interaction with hemagglutinin fusion peptide (Holm et al., 2016).   
Vaccine adjuvants are essential to the success of a vaccine by enhancing 
immunogenicity, reducing the antigen dose and the number of immunizations and 
potentiating a durable and fast T cell immune response and long lasting antibody production.  
Currently available influenza vaccines trigger a strain-specific immune response 
unfortunately obsolete against new influenza viruses or mutated substrains.  Aluminium salts 
and MF59® are the major licensed adjuvants used in influenza vaccines.  Although it is 
thought that the induced inflammation represent an important part of the adjuvancity of 
Aluminium Hydroxyde, its use results in necrosis of muscle fibers and inflammation with 
edema and infiltration od leukocytes.  MF59® increases chemokine and inflammatory 
cytokine production and induces the recruitment of monocytes and neutrophils and the site 
of injection.  Nonetheless, the injection of those adjuvanted vaccines induces local 
inflammatory reaction associated with clinical experiences of redness, swelling and pain at 
the injection site.   
Several STING agonists vaccine formulations have been recently tested: cyclic 
dinucleotides adjuvanted formulations have demonstrated great antitumor potential in 
multiple therapeutic models of established cancer (Fu et al., 2015) and encapsulated 
dinucleotides with lipid nanoparticles demonstrated potent antigen delivery and stimulation 
in the draining lymph nodes in models of anti-tumor and anti HIV gp41 vaccination (Hanson 
et al., 2015). 
 
Skin vaccines, advantages inconvenients, future/ recent developments… 
 
Wang and colleagues demonstrate that the small STING natural agonist 
cGAMP has a great potential as influenza vaccine adjuvant.  Indeed, intradermal vaccination 
with cGAMP induces a greater IFN-  and a higher IgG2a 
antibody titer when compared to intramuscular immunization with cGAMP or AddaVax™ – 
the squalene-based oil-in-water emulsion similar to MF59® - influenza vaccine formulations 
(Wang et al., 2016).  Furthermore, they show that cGAMP influenza vaccine formulation 
induces very little to no inflammation at the site of injection and that neither dermis or 
epidermis are affected unlike other adjuvants such as resiquimod, a R848 small molecule 
agonist for TLR7/8 able to induce a strong type I IFN/ Th1 response similarly to single 
stranded viral RNAs.   
 
 
 
Conflict of Interest 
The authors state no conflict of interest. 
 
  
Aguirre S, Maestre AM, Pagni S, Patel JR, Savage T, Gutman D, et al. DENV inhibits 
type I IFN production in infected cells by cleaving human STING. PLoS Pathog. 
2012;8(10):e1002934. 
 
Fu J, Kanne DB, Leong M, Glickman LH, McWhirter SM, Lemmens E, et al. STING 
agonist formulated cancer vaccines can cure established tumors resistant to 
PD-1 blockade. Sci Transl Med. 2015;7(283):283ra52. 
 
Hanson MC, Crespo MP, Abraham W, Moynihan KD, Szeto GL, Chen SH, et al. 
Nanoparticulate STING agonists are potent lymph node-targeted vaccine 
adjuvants. The Journal of clinical investigation. 2015;125(6):2532-46. 
 
Holm CK, Rahbek SH, Gad HH, Bak RO, Jakobsen MR, Jiang Z, et al. Influenza A 
virus targets a cGAS-independent STING pathway that controls enveloped RNA 
viruses. Nat Commun. 2016;7:10680. 
 
Lahaye X, Satoh T, Gentili M, Cerboni S, Conrad C, Hurbain I, et al. The capsids of 
HIV-1 and HIV-2 determine immune detection of the viral cDNA by the innate 
sensor cGAS in dendritic cells. Immunity. 2013;39(6):1132-42. 
 
Marichal T, Ohata K, Bedoret D, Mesnil C, Sabatel C, Kobiyama K, et al. DNA released 
from dying host cells mediates aluminum adjuvant activity. Nat Med. 
2011;17(8):996-1002. 
 
Stetson DB, Medzhitov R. Type I interferons in host defense. Immunity. 
2006;25(3):373-81. 
 
Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMP-AMP synthase is a cytosolic DNA 
sensor that activates the type I interferon pathway. Science. 
2013;339(6121):786-91. 
 
Wang J, Li P, Wu MX. Natural STING agonist as an "ideal" adjuvant for cutaneous 
vaccination. J Invest Dermatol. 2016. 
 
 
